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PURPOSE. Vitamin D3 is a secosteroid mainly synthesized from the conversion of the skin
precursor 7-dehydrocholesterol (7DHC) to vitamin D3 by ultraviolet (UV) B sunlight.
Extrarenal synthesis of vitamin D3 has been reported in many tissues and cells, including
barrier sites. This study characterizes the expression of components of vitamin D3 signaling in
human ocular barrier cells.
METHODS. Primary human scleral fibroblasts (HSF), human corneal endothelial (HCEC-12),
nonpigmented ciliary body epithelial (ODM-2), and adult retinal pigment epithelial (ARPE-19)
cell lines were analyzed for the expression of vitamin D receptor (VDR), the vitamin D3
activating enzymes 1a-hydroxylase (CYP27B1), 25-hydroxylases (CYP27A1 and CYP2R1), the
vitamin D3 inactivating enzyme 24-hydroxylase (CYP24A1), and the endocytic receptors
cubilin and megalin using a combination of RT-PCR, immunocytochemistry, and enzyme
immunoassay (EIA).
RESULTS. The HSF, HCEC-12, ODM-2, and ARPE-19 express mRNA and protein for all vitamin D3
synthesizing and metabolizing components. The cell types tested, except HSF, are able to
convert inactive 25-hydroxyvitamin D3 (25[OH]D3) into active 1,25-hydroxyviatmin D3
(1,25[OH]2D3).
CONCLUSIONS. This novel study demonstrated that ocular barrier epithelial cells express the
machinery for vitamin D3 and can produce 1,25(OH)2D3. We suggest that vitamin D3 might
have a role in immune regulation and barrier function in ocular barrier epithelial cells.
Keywords: vitamin D3, blood–ocular barrier, epithelial cells
Vitamin D3 is a secosteroid synthesized from the conversionof the precursor 7-dehydrocholesterol (7DHC) in the skin
to vitamin D3 by ultraviolet (UV) B sunlight. To a lesser extent,
vitamin D3 can be obtained from the diet. Sufficient levels of
vitamin D3 are required for calcium absorption and mainte-
nance of healthy bones.1 In the circulation, vitamin D3 is
activated by two successive hydroxylation steps. The first
occurs in the liver by a cytochrome P (CYP) 450 enzyme, 25-
hydroxylase (mitochondrial CYP27A1 and microsomal
CYP2R1) to produce the major circulating form 25-hydroxyvi-
tamin D3 (25[OH]D3). The second hydroxylation step occurs in
the kidney, where 25-hydroxyviatmin D 1a-hydroxylase
(CYP27B1) catalyzes the conversion of 25(OH)D3 to its active
form 1,25-dihydroxyvitamin D3 (1,25[OH]2D3). As a feedback
mechanism, 24-hydroxylase (CYP24A1), which is induced by
1,25(OH)2D3, inactivates both forms of vitamin D3. The
1,25(OH)2D3 action is mediated via the vitamin D receptor
(VDR) that heterodimerizes with retinoid X receptor (RXR), a
complex that regulates gene transcription through binding to
vitamin D response elements (VDRE) in the promoter region of
target genes.2
Extrarenal synthesis of vitamin D3 has been reported in
many tissues and cells, including barrier sites. The VDR and
CYP27B1 have been described in epithelial cells of skin, lung,
intestine, prostate, endometrium, and breast, as well as cells of
the immune system, such as macrophages and dendritic
cells.3–9 In the circulation, 25(OH)D3 is bound to vitamin D
binding protein (DBP), which facilitates its cellular uptake by
multi-ligand endocytic receptors megalin/cubilin expressed on
the apical surface of polarized epithelial cells in many tissues.10
Local production of 1,25(OH)2D3 has been shown in
respiratory, bladder, and colonic epithelial cells; osteoclasts;
and macrophages.4,11–14 Of note, VDR is critical for barrier
formation in human skin and the integrity of mucosal barrier in
mouse intestine.15,16 Recently, vitamin D3 has been recognized
as an immunomodulatory hormone that regulates innate and
acquired immune responses.17 One regulatory role of
1,25(OH)2D3 in the immune system (in vitro) involves the
inhibition of proinflammatory cytokine production from CD4þ
T cells and the induction of a regulatory T cell phenotype.18
Endogenous conversion of 25(OH)D3 has been shown to
inhibit dendritic cell antigen presentation and chemotaxis.19
The ability to induce the production of host defense peptides
(HDPs) in blood monocytes also supports an interaction
between 1,25(OH)2D3 and the immune system. The HDP LL-
37 (cathelicidin) and human beta defensins (hBD1-4) can kill a
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wide range of Gram-negative and Gram-positive bacteria, as
well as viruses. Moreover, HDPs are immunomodulatory
molecules.20 They can act as chemotactic agents for T and
dendritic cells, as well as their ability to induce T-helper 1 and 2
cytokines.21
Ocular immune privilege is maintained by a cluster of
anatomic and physiological processes that protect the eye from
sight-threatening infections and inflammatory responses.22 The
sclera is the white, opaque, fibrous support to the global
structure of the eye composed of a rich extracellular matrix
(ECM) of collagen and elastic fibers, together with fibroblasts
that are responsible for tissue remodeling and the regeneration
of the ECM.23 On the posterior surface of the cornea,
endothelial cells contribute to barrier function by mediating
sodium transport, which maintains the cornea in a relatively
dehydrated state, thereby preserving corneal transparency.24
The eye consists of two key vascular barriers that afford
protection: the blood–aqueous barrier and the blood–retinal
barrier. The blood–aqueous barrier consists of tight junctions
between vascular endothelial cells of iridociliary body blood
vessels, the nonpigmented ciliary epithelial cells complexed
apically with the pigmented ciliary epithelium, and the
posterior iris epithelium, whereas the blood–retinal barrier is
composed of tight junctions of endothelial cells in retinal
vasculature and those between the retinal pigment epithelial
cells.25
To date, very few studies have examined the presence of
vitamin D3 synthesizing and metabolizing pathways in the eye,
and whether these have a role in ocular barrier cell function by
the autocrine production of vitamin D3. This study shows the
expression and functionality of vitamin D3 system in several
human ocular barriers, intimating that vitamin D3 may be
important to the ocular barrier function and ocular immune
privilege.
MATERIALS AND METHODS
Cell Culture
All cells were grown in a humidified chamber at 378C and 5%
CO2, and passaged by trypsinization. Penicillin (100 units/mL)
and streptomycin (100 lg/mL) solution was added to all
growth media (PAA Laboratories, Yeovil, UK). All cells were
grown in 10% heat inactivated fetal calf serum (HIFCS) except
human corneal endothelial cells, which were grown in 5%
HIFCS (Biosera Ltd., Ringmer, UK).
Primary Human Scleral Fibroblasts (HSF). Primary
human scleral fibroblasts were generated from redundant
donated corneal scleral tissue following corneal transplant
surgery. Acquisition of tissue was after approval from the local
research ethics committee and adhered to the Declaration of
Helsinki. The sclera was cut into 3- to 5-mm sections and
layered in a T-25 cm2 tissue culture flask (Sarstedt, Leicester,
UK) for 3 to 5 days in fibro-medium (RPMI 1640 containing 1%
MEM nonessential amino acid and 1% sodium pyruvate) until
the fibroblasts grew out from the explant and maintained in
fibro-medium (all Sigma-Aldrich, Dorset, UK).
Corneal Endothelial (HCEC-12) Cells. The HCEC-12 cell
line (the German Resource Centre for Biological Material,
DSMZ, Braunschweig, Germany) was grown in tissue culture
flasks (Sarstedt, Leicester, UK) precoated with a mixture of
laminin and chondroitin sulfate (Sigma-Aldrich) in F99 basal
medium (Gibco, Invitrogen, Paisley, UK) supplemented with
20 lg/mL ascorbic acid, 20 lg/mL human recombinant insulin,
and 10 ng/mL basic fibroblast growth factor (bFBF; all Sigma-
Aldrich).
Adult Retinal Pigment Epithelial (ARPE-19). The ARPE-
19 line, an SV40 transformed cells line, obtained from
American Type Culture Collection (ATCC number: CRL-2302;
American Type Culture Collection, Middlesex, UK) was
cultured in Dulbecco’s modified Eagle’s medium: Nutrient
Mixture F-12 (DMEM/F12), with glutamax (Gibco, Invitrogen).
Nonpigmented Ciliary Body Epithelial (ODM-2). The
ODM-2 cell line was a kind gift from Dr Coca Prados
(Department of Ophthalmology and Visual Sciences, Yale
University, New Haven, CT, USA). Cells were cultured in high
glucose (4 g/L) DMEM (PAA Laboratories) as described
previously.26
Reverse Transcription and PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Crawley, UK) according to manufacturer’s instructions. The
RNA concentration and purity were determined using Nano-
drop spectrophotometer (Thermo Fisher Scientific, Lough-
borough, UK). Total RNA (1 lg) was reverse transcribed to
cDNA using Taqman reverse transcription kit (Applied
Biosystems, Warrington, UK) following manufacturer’s instruc-
tions. The PCR was performed using GoTaq Flexi DNA
polymerase system (Promega, Southampton, UK) in a total
volume of 20 lL containing cDNA (1 lL for 18S and 2 lL for all
other primers), 2 mM MgCl2,31 GoTaq green Flexi Buffer, 0.5
U Gotaq DNA polymerase, 0.25 mM dNTP mix (Promega), 2.5
lM 18S, and 5 lM other forward and reverse primers (Alta
Bioscience, Birmingham, UK). The PCR was performed using
Gene Amp, PCR System 2700 (Applied Biosystems) as follows:
5 minutes at 948C, followed by three temperature cycles of 1
minute at 948C, annealing for 60 seconds, and 1 minute at
728C. For cubilin and megalin, preamplification was carried out
at 958C for 5 minutes followed by cycles of denaturation at
948C for 45 seconds, annealing for 45 seconds, and extension
at 728C for 45 seconds. All PCR reactions ended with a final
extension step at 728C for 7 minutes. Primer sequences, taken
from previous publications and cycling condition were as
shown in Table 1.
TABLE 1. Polymerase Chain Reaction Primer Sequence and Cycle Conditions
Gene
Forward
Primer 50–30
Reverse
Primer 50–30 Cycles
Annealing
Temperature, 8C
Product,
bp
VDR CGCTCCAATGAGTCCTTCACC GCTTCATGCTGCACTCAGGC 33 61 421
CYP27B1 CACCTGACCCACTTCCTGTT TCTGGGACACGAGAATTTCC 35 58 302
CYP24A1 CCCACTAGCCACCTCGTACCAAC CGTAGCCCTTCTTTGCGGTAGTC 35 60 485
CYP2R1 AGAGACCCAGAAGTGTTCCAT GTCTTTCAGCACAGATGAGGTA 40 62 259
CYP27A1 GGCAAGTACCCAGTACGG AGCAAATAGCTTCCAAGG 40 62 292
18S GTTGGTGGAGCGATTTGTCT GGCCTCACTAAACCATCCAA 20 55 400
Cubilin GCGGCTTCACTGCTTCCTA GAGTGATGGTGTGCCCTTGT 35 53 518
Megalin TAAGTCAGTGCCCAACCTTT GCGGTTGTTCCTGGAG 35 53 290
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1,25(OH)2D3 Enzyme Immunoassay (EIA)
Cells were grown to confluence in 12-well culture plates. Cells
were placed in serum-free medium and were either left
untreated or treated with 25(OH)D3 (10
7 M) with or without
pretreatment with ketoconazole (105 M), an inhibitor of
CYP27B1 (both Sigma-Aldrich) for 2 hours. After 24 hours, cell
culture supernatants were collected for the measurement of
1,25(OH)2D3, and cells were processed for protein extraction
and quantification. The 1,25(OH)2D3 concentration was
measured by EIA (Immunodiagnostics Systems Limited, Tyne
& Wear, UK) according to the manufacturer’s instructions.
Immunofluorescence
Ocular barrier cells were cultured in 8-well glass chamber
slides (BD Biosciences, Oxford, UK), fixed for 20 minutes with
cold methanol at 48C, and rinsed with PBS. Cells were blocked
with 5% BSA in PBS for 1 hour, then treated with mouse anti-
human VDR clone H4537 (R&D Systems, Abingdon, UK),
sheep anti-human CYP27B1 clone H210 (The Binding Site Ltd.,
Birmingham, UK), mouse anti-human CYP24A1 clone 1E1
(Novus Biologicals, Cambridge, UK), mouse anti-human
mannose-6-phosphate receptors (M6P) clone 2G11 (Abcam,
Cambridge, UK), or mouse anti-human trans-Golgi network 38
(TGN38) clone 2F7.1 (Novus Biologicals), respectively (1:100
in PBS blocking solution) for 1 hour at room temperature. Cells
were washed several times with PBS, then incubated with FITC
conjugated anti-mouse or FITC conjugated anti-sheep second-
ary antibody (The Binding Site Ltd.), or Texas Red (TR)
conjugated anti-mouse antibody (Abcam) diluted 1:250 in
blocking solution for 1 hour at room temperature. Cells were
counterstained briefly with DNA-specific stain DAPI (Gibco,
Invitrogen) and mounted (Vectashield; Vector Laboratories,
Peterborough, UK). Staining was detected using a fluorescent
microscope (AxioPlan2 Imaging; Zeiss, Cambridge, UK).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA, USA). The Kruskal-
Wallis test was used, followed by Dunn’s multiple comparison
test to compare differences between groups. Data are
expressed as mean 6 SD and a P value < 0.05 was considered
as statistically significant.
RESULTS
Ocular Barrier Cells Constitutively Express mRNA
for Vitamin D3 Metabolism
Extrarenal expression of vitamin D3 synthesizing and metab-
olizing components has been described in many organs. To
examine the presence of these elements in ocular barriers,
mRNA expression was examined by RT-PCR. The VDR was
expressed strongly in all ocular cells tested (Fig. 1A). The
CYP27B1 was expressed markedly by HCEC-12, ODM-2, and
ARPE-19 compared to a weak expression in HSF. In contrast,
CYP24A1 was expressed strongly by HSF and weakly by all
other cell types. The CYP27A1 was expressed weakly in HCEC-
12, ARPE-19, and ODM-2, but was undetected in HSF. The HSF,
HCEC-12, and ARPE-19 highly expressed CYP2R1, whereas
ODM-2 showed a weak expression. The mRNA expression of
cubilin and megalin, the receptors required for the internali-
zation of 25(OH)D3 through DBP, also was investigated. Cubilin
was expressed strongly in all cells, while megalin was only
weakly expressed in HSF (Fig. 1B). To summarize, ocular
barrier cells constitutively express mRNA for vitamin D3
metabolism.
Ocular Barrier Cells Express Proteins for Vitamin
D3 Metabolism
Immunofluorescent staining of all cell types for the different
vitamin D3 elements was performed (Fig. 2, Supplementary
Figs. S1A–D). The intensity of staining varied between cell
types, but all cells were positive for all vitamin D3 proteins. The
VDR showed a diffuse mild cytoplasmic and abundant
speckled nuclear staining. The expression was the strongest
in ODM-2 and HCEC-12, and weaker in ARPE-19 and HSF,
respectively. The CYP24A1 also was present in the cytoplasm,
where the signal was strong in HCEC-12 and ODM-2, and weak
in HSF and ARPE-19. The CYP27B1 showed an intense
cytoplasmic pattern in ODM-2 and ARPE-19, while HSF showed
moderate staining. Interestingly, in HCEC-12 cells, diffuse
cytoplasmic staining was present, but most of the enzyme
appeared within a perinuclear vesicle.
CYP27B1 Colocalizes With MPRs and TGN38 in
HCEC-12 Cells
The YP27B1 normally is located in the inner membrane of the
mitochondria.3 All the ocular cells demonstrated a staining
pattern consistent with this expression, that is, cytoplasmic.
The exception was HCEC-12 cells, which not only expressed
CYP27B1 in the cytoplasm, but the majority of the enzyme
appeared as a vesicle adjacent to the nucleus. To further
identify the nature of this vesicle-like structure, HCEC-12 were
stained for Mannose 6 phosphate (M6P) receptors that are
known to have a role in the transport of enzymes from the
trans-Golgi network (TGN) to lysosomes27 and typically shows
perinuclear localization. In addition, TGN38 protein, part of
the trans-Golgi network that directs proteins to secretory
vesicles, lysosomes, or plasma membrane, also was exam-
FIGURE 1. Ocular barrier cells express mRNA for vitamin D3 elements.
Conventional RT-PCR was carried out using total RNA extracted from
ocular barrier epithelial cell lines and two primary HSF samples (1 and
2), and primers for (A) VDR, CYP27B1, CYP24A1, CYP27A1, CYP2R1,
and for (B) cubilin, and megalin. Ribosomal 18S was used as an internal
PCR control and water was used a negative PCR control. The HKC-8
cells were used as a positive control for vitamin D machinery, and
primary thyroid cells were used as a positive control for cubilin and
megalin. Results are representative of at least three independent
experiments. Molecular sizes (base pairs [bp]): 18S (400), VDR (421),
CYP27B1 (302), CYP24A1 (485), CYP27A1 (292), CYP2R1 (259),
cubilin (518), and megalin (290), and these show the constitutive
expression of vitamin D3 synthesizing components in ocular barrier
cells.
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ined.28 The CYP27B1 colocalized to M6P receptors and TGN38
in HCEC-12 (Fig. 3A). The cytoplasmic staining, together with
the perinuclear punctated presence (Fig. 3B) confirm
CYP27B1 presence in the TGN in HCEC-12 cells.
Ocular Barrier Cells Can Convert Inactive Vitamin
D3 to the Active Form 1,25(OH)2D3
Ocular barrier cells have the molecular components necessary
to produce 1,25(OH)2D3 locally. We next examined the
functional capacity of CYP27B1 and its ability to convert
inactive 25(OH)D3 (10
7 M) into active 1,25(OH)2D3. The rate
of conversion was variable among the different cells, where
the highest levels were produced by HCEC-12 followed by
HKC8 then ODM2, while the lowest levels were seen in ARPE-
19 and none was detected in HSF (Fig. 4).
The HKC-8–positive control cells produce significant
amounts of 1,25(OH)2D3 (195.4 pmol/L/mg protein, P <
0.05). By comparison, primary HSF did not show any
conversion and ARPE-19 cells showed minimal levels (8.0
and 25.0 pmol/L/mg protein, respectively). Interestingly,
HCEC-12 were the most efficient of all cell types at converting
the substrate into the active form of 1,25(OH)2D3 (2068.1
pmol/L/mg protein, P < 0.01), that is, 10 times higher than
HKC-8, while ODM-2 cells produced levels as high as 640.1
pmol/L/mg protein.
Substrate conversion in each cell type was inhibited by
pretreatment with 105 M ketoconazole and the inhibition is
statistically significant in cells that produced more than 200
pmol/L/mg protein of 1,25(OH)2D3 (HCEC-12, and ODM-2).
DISCUSSION
This study showed that human ocular barrier epithelial cells
and scleral fibroblasts constitutively express the receptor and
the metabolic enzymes required in the vitamin D3 pathway,
and for the first time to our knowledge that all these cell types
can endogenously produce 1,25(OH)2D3 when treated with
physiological concentrations of its precursor 25(OH)D3 (Table
2). These findings supported a recent report describing
CYP27B1 and VDR mRNA in primary human corneal epithe-
lium (PHCEC), while treatment with 25(OH)D3 or
1,25(OH)2D3 enhanced barrier function as shown by de-
creased inulin permeability and increased transepithelial
resistance in vitro.29 In a separate study, a human corneal
limbal epithelial cell line treated with UVB and 7DHC showed
an increase in 1,25(OH)2D3 production.
30 Previous studies also
have shown that corneal epithelial cells and RPE-choroid
express the molecular elements for vitamin D3, but there were
no data on 25(OH)D3 conversion.
31
As stated, vitamin D3 synthesizing components (VDR,
CYP27B1, and CYP24A1) are expressed widely in many human
epithelial cells. In agreement with the speckled cytoplasmic
and nuclear VDR staining in ocular barrier cells and sclera
fibroblasts, VDR has been described in cytoplasm and nucleus
of bladder epithelium as well as skin fibroblasts.11,32 The
cytoplasmic expression of CYP27B1 in most of the ocular
barrier cells is in accordance with similar expression in bladder
epithelium. Conversely, the punctate perinuclear staining of
CYP27B1 in HCEC-12 can be compared to the cytoplasmic
localization of internalized Alexa-DBP in the perinuclear space
of human breast cancer epithelial cells T-47D, where it
FIGURE 2. Ocular barrier cells express proteins for vitamin D3 elements. Ocular epithelial cell lines and primary HSF cells were grown to 40% to
50% confluency in 8-well chamber slides, then fixed and processed for immunofluorescence. Cells were stained with primary mouse monoclonal
anti-human VDR antibody, mouse anti-human CYP24A1, and sheep polyclonal anti-human CYP27B1 antibodies, respectively. Staining was visualized
with secondary FITC (green) conjugated anti-mouse and anti-sheep antibodies, respectively, using fluorescence microscopy. Nuclei were stained
with DAPI (blue). This figure shows merged images with magnification:320 for HSF and340 for the others, and these show the expression patterns
of vitamin D3 synthesizing proteins in ocular barrier cells. Scale bars: 20 lm.
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colocalized with lysosomes, which suggested that DBP traffics
through endosomes and lysosomes.33 The expression of
CYP27B1 in TGN could be part of this enzyme’s trafficking
in these cells. Membrane-bound CYP450 proteins can recycle
through Golgi before reaching their destined locations.34
Although ocular barrier cells show constitutive expression
of mRNA and protein for CYP24A1, this mitochondrial enzyme
is not constitutively expressed in all peripheral organs and
tissues. Some cells, such as skin keratinocytes, primary
respiratory epithelial cells, and colonic epithelial cell line,
only express CYP24A1 in response to 25(OH)D3 or
1,25(OH)2D3. Keratinocytes demonstrate a strong up-regula-
tion following exposure to UVB light in the presence of
7DHC.4,13,35 The CYP24A1 also is induced after treatment with
25(OH)D3 sufficient serum in macrophages.
20
Our study showed that ocular barrier epithelial cells can
convert inactive vitamin D3 to its active form. With the
exception of ARPE-19, ocular barrier cells, are able to produce
significant levels of active 1,25(OH)2D3 (>0.43 109 M) at 24
hours. This rate of conversion is comparable to that of primary
FIGURE 3. CYP27B1 co-localizes with M6P receptor and TGN38 in HCEC-12 . (A) Fluorescence microscopy images showing HCEC-12 cells grown
to 40% to 50% confluency in 8-well chamber slides, then fixed and processed for immunofluorescence. Cells were stained with sheep polyclonal
anti-human CYP27B1 and mouse monoclonal anti-human M6P and TGN38, respectively. Staining was visualized with FITC (green) and TR (red)
conjugated anti-sheep and anti-mouse antibodies, respectively. Nuclei were stained with DAPI (blue). Results show colocalization of CYP27B1 with
M6P (top) and TGN38 (middle). Negative control (bottom): cells with primary antibody omitted (bottom). Magnification:3100 for M6P and TGN38
and 340 for negative control. Scale bars: 5 lm for M6P and TGN38, and 20 lm for negative control. (B) Confocal microscopy images showing
HCEC-12 cells prepared as above and were stained with primary sheep polyclonal anti-human CYP27B1 antibodies. Staining was visualized with
secondary FITC (green) conjugated anti-sheep antibodies. Nuclei were stained with DAPI (gray). Magnification:340. Results show the perinuclear
localization of CYP27B1 in HCEC-12 cells.
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FIGURE 4. Ocular barrier cells can convert 25(OH)D3 into active 1,25(OH)2D3. Ocular epithelial cells lines grown to 80% confluency in 12-well
plates were either left untreated or treated with 25(OH)D3 (10
7 M) for 24 hours with or without pretreatment with CYP450 inhibitor (105 M)
ketoconazole (KC) for 2 hours. Cell culture supernatants were collected and 1,25(OH)2D3 was determined by enzyme immunoassay. Results were
obtained from a standard curve as pmol/L, then corrected per mg of protein. The HKC-8 cells were used as a positive conversion control. Results are
representative for at least three independent experiments. Graph shows mean 6 SD 1,25(OH)2D3 per mg protein for each treatment. Bottom right
graph shows conversion rates in all ocular barrier epithelial cells compared to HKC-8. Kruskal-Wallis test with Dunn’s posttest were performed (*P
< 0.05, **P < 0.01; ns, not significant). Results show that all ocular barrier cells except HSF convert inactive to active 1,25(OH)2D3.
TABLE 2. A Summary of Gene and Protein Expression for Vitamin D3 Elements by Ocular Barrier Cells as Well as the Rate of 25D3 Conversion
Cell Line
Gene Expression Immunofluorescence
Rate of 25D3
ConversionVDR CYP27B1 CYP24A1 CYP27A1 CYP2R1 Cubilin Megalin VDR CYP27B1 CYP24A1
Ocular barrier cells
HSF þþ þþ   þþþ þþþ þ þþ þþ þþþ 
HCEC-12 þþþ þþþ þ þþ þþþ þþþ  þþþ þþþ þ þþþ
ODM-2 þþþ þþþ þ þ þþ þþþ  þþþ þþþ þ þþ
ARPE-19 þþþ þþþ þþ þ þþþ þþþ  þþ þþþ þþ þ
Control cells
HKC-8 þþþ þþþ þþþ þ þþþ þþþ þ ND ND ND þþ
Thyroid ND ND ND ND ND þþþ þþþ ND ND ND ND
Ocular barrier cell lines are shown with mRNA expression, immunofluorescence staining intensity, and rate of 25D3 conversion with the highest
asþþþ and the lowest asþ. The HKC-8 cell line was used as a positive control for the expression of vitamin D3 pathway components and 25(OH)D3
conversion. Thyroid mRNA was used a positive control for the expression of cubilin and megalin. ND, not done.
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respiratory epithelial cells, bladder, and mammary epithelial
cell lines.4,11,36 These rates are much higher than those
produced by human kidney cortical collecting duct (HCD)
cell line.37 As depicted in Figure 5, ocular barrier conversion is
high in PHCEC (Susarla R, Wallace GR, Oswal K, et al.,
unpublished data, 2013), reaches a peak in corneal endothe-
lium (HCEC-12), and starts to decrease in nonpigmented ciliary
body epithelium (ODM-2), reaching the lowest levels at retinal
pigmented epithelium (ARPE-19). The HSF failed to convert
25(OH)D3 into 1,25(OH)2D3 and likewise dermal fibroblasts do
not express CYP27B1, which may indicate that fibroblasts
generally do not have the ability to convert 25(OH)D3.
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Ocular barrier epithelial cells appear to be efficient in
producing 1,25(OH)2D3 provided they have the substrate
available. Despite the requirement of 25(OH)D3 for CYP27B1
to convert it to 1,25(OH)2D3, ocular barrier cells potentially
can initiate the vitamin D3 pathway as early as the first 25-
hydroxylation step via CYP27A1 and CY2R1. Extrahepatic
expression of CYP27A1 and CY2R1 also has been reported
previously in other tissues.39,40 With its broad substrate
specificity, CYP27A1 also is involved in cholesterol metabo-
lism. The CYP27A1 is expressed in the retinal pigment
epithelium and protects the retina from the toxic 7-ketocho-
lesterol, a metabolite of 7-DHC as a result of photooxidation.
Although CYP27A1 was expressed weakly by ocular barrier
cells, the expression of microsomal CYP2R1 was considerably
stronger. Moreover, the 25-hydroxylation activity of CYP2R1 is
26-fold higher than that of CYP27A1.41 This means ocular cells
may be able to synthesize vitamin D3 directly on exposure to
sunlight. However, it should be noted that the American
Academy of Ophthalmology recommends protection of the eye
from long hours of direct sunlight, which may contribute to
cataract and cancer formation.
The expression of megalin and cubilin in ocular barrier cells
indicated the importance of these receptors in vitamin D3
metabolism. Although megalin is expressed more widely in
different tissues, the expression of cubilin is more pronounced
in ocular barrier cells.10,42
An immune privileged organ, such as the eye, requires
efficient strategies that can protect it from sight-threatening
infections and damaging inflammatory responses. A recent
study has shown that mice injected with vitamin D3 had
reduced retinal inflammation and this was associated with a
reduction of retinal macrophage activation. More importantly,
these mice showed decreased levels of amyloid-beta (Ab), a risk
factor for age-related macular degeneration (AMD).43 De-
creased serum levels in humans of 25(OH)D3 have been
correlated with increased early AMD and low visual acuity in
the elderly.44 This was investigated further by calculating UVB
exposure index, which correlated with reduced neovascular
AMD. Moreover, single nucleotide polymorphisms of human
CYP24A1 have been shown to be linked to neovascular AMD.31
The ability of ocular barrier cells to locally produce large
amounts of 1,25(OH)2D3 may be important for their barrier
function. For example, corneal endothelial cells are highly
metabolic and represent an important barrier at the anterior
segment of the eye, and producing large amounts of
1,25(OH)2D3 may help maintain this function. More than 200
genes were significantly upregulated or downregulated in
response to stimulation with 1,25(OH)2D3, including several
involved in the immune response.45
The main caveat in this work is the use of cell lines rather
than primary cells. However the lines used are well-established
and regarded as good correlates for freshly-isolated ocular cells
in multiple experiments.
In conclusion, this study has demonstrated for the first time
to our knowledge the expression of vitamin D3 synthesizing
components in ocular barrier cells, and that these cells can
convert inactive 25(OH)D3 into active 1,25(OH)2D3. Further
work will show if these cells can create an environment rich in
1,25(OH)2D3 and if this has an effect on ocular immune
protection and immune privilege.
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